Quipt Home Medical to Begin Trading on Nasdaq
May 27 2021 - 8:00AM
Quipt Home Medical Corp. (“
Quipt” or the
“
Company”) (NASDAQ: QIPT; TSXV: QIPT), a U.S.
based leader in the home medical equipment industry, focused on
end-to-end respiratory care, is pleased to announce the start of
trading on The Nasdaq Capital Market (“
Nasdaq”),
under the trading ticker symbol “QIPT” at the market open today.
The Company’s common shares will continue to be listed on the TSX
Venture Exchange under the symbol “QIPT”.
Quipt utilizes a technology-driven, patient
centric model to meet the one-of-a-kind needs of every patient in
its ecosystem. Supported by the reach and the reputation of local
brands, the Company strives to enrich the lives of its patients by
providing full-service home respiratory solutions to suit every
kind of need, for every kind of patient. Quipt operates out of 51
locations in 11 states with over 17,000 referring physicians and
approximately 120,000 current active patients.
“Today marks the culmination of the hard work
and dedication of the Quipt entire team. We are extremely excited
to join Nasdaq at such an important time within our company’s
history,” commented Greg Crawford, CEO and Chairman of Quipt.
“Given our strong growth, we believe this listing will further
enhance our visibility globally, allowing us to garner awareness
with a larger audience of institutional investors and ultimately
unlock shareholder value and increase liquidity in the future.”
As a reminder, Quipt will host its Q2 Fiscal
2021 earnings conference call and audio webcast on Tuesday, June 1,
2021 at 10:00 a.m. (EST).
Conference Call Details:
Canada/US Toll
Free: |
1 (800) 319
4610 |
International: |
1 (604) 638 5340 |
Audio Webcast Details:
The live audio webcast can be found on the
investor section of the Company’s website through the following
link: www.quipthomemedical.com
ABOUT QUIPT HOME MEDICAL
CORP.
The Company provides in-home monitoring and
disease management services including end-to-end respiratory
solutions for patients in the United States healthcare market. It
seeks to continue to expand its offerings to include the management
of several chronic disease states focusing on patients with heart
or pulmonary disease, sleep disorders, reduced mobility and other
chronic health conditions. The primary business objective of the
Company is to create shareholder value by offering a broader range
of services to patients in need of in-home monitoring and chronic
disease management. The Company’s organic growth strategy is to
increase annual revenue per patient by offering multiple services
to the same patient, consolidating the patient’s services and
making life easier for the patient.
Forward-Looking Statements
Certain statements contained in this press
release constitute "forward-looking information" as such term is
defined in applicable Canadian and United States securities
legislation. The words "may", "would", "could", "should",
"potential", "will", "seek", "intend", "plan", "anticipate",
"believe", "estimate", "expect" and similar expressions as they
relate to the Company, including the anticipated results of a
listing on Nasdaq, are intended to identify forward-looking
information. All statements other than statements of historical
fact may be forward-looking information. Such statements reflect
the Company's current views and intentions with respect to
future events, and current information available to the Company,
and are subject to certain risks, uncertainties and assumptions.
Many factors could cause the actual results, performance or
achievements that may be expressed or implied by such
forward-looking information to vary from those described herein
should one or more of these risks or uncertainties materialize.
Examples of such risk factors include, without limitation: credit;
market (including equity, commodity, foreign exchange and
interest rate); liquidity; operational (including technology and
infrastructure); reputational; insurance; strategic;
regulatory; legal; environmental; capital adequacy; the general
business and economic conditions in the regions in which the
Company operates; the ability of the Company to execute on key
priorities, including the successful completion of acquisitions,
business retention, and strategic plans and to attract, develop
and retain key executives; difficulty integrating newly acquired
businesses; the ability to implement business strategies and
pursue business opportunities; low profit market segments;
disruptions in or attacks (including cyber-attacks) on the
Company's information technology, internet, network access or
other voice or data communications systems or services; the
evolution of various types of fraud or other criminal behavior
to which the Company is exposed; the failure of third parties to
comply with their obligations to the Company or its affiliates;
the impact of new and changes to, or application of, current laws
and regulations; decline of reimbursement rates; dependence on
few payors; possible new drug discoveries; a novel business model;
dependence on key suppliers; granting of permits and licenses
in a highly regulated business; the overall difficult
litigation environment, including in the United States;
increased competition; changes in foreign currency rates; increased
funding costs and market volatility due to market illiquidity
and competition for funding; the availability of funds and
resources to pursue operations; critical accounting estimates and
changes to accounting standards, policies, and methods used by
the Company; the occurrence of natural and unnatural catastrophic
events and claims resulting from such events; and risks
related to COVID-19 including various recommendations, orders and
measures of governmental authorities to try to limit the
pandemic, including travel restrictions, border closures,
non-essential business closures, quarantines,
self-isolations, shelters-in-place and social distancing,
disruptions to markets, economic activity, financing, supply
chains and sales channels, and a deterioration of general
economic conditions including a possible national or global
recession; as well as those risk factors discussed or referred
to in the Company’s disclosure documents filed with United States
Securities and Exchange Commission and available at www.sec.gov,
and with the securities regulatory authorities in certain provinces
of Canada and available at www.sedar.com. Should any factor affect
the Company in an unexpected manner, or should assumptions
underlying the forward-looking information prove incorrect, the
actual results or events may differ materially from the
results or events predicted. Any such forward-looking information
is expressly qualified in its entirety by this cautionary
statement. Moreover, the Company does not assume responsibility
for the accuracy or completeness of such forward-looking
information. The forward-looking information included in this
press release is made as of the date of this press release and
the Company undertakes no obligation to publicly update or
revise any forward-looking information, other than as required by
applicable law.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information please visit our website
at www.quipthomemedical.com, or contact:
Cole StevensVP of Corporate Development Quipt
Home Medical Corp.859-300-6455cole.stevens@myquipt.com
Gregory CrawfordChief Executive OfficerQuipt
Home Medical Corp.859-300-6455investorinfo@myquipt.com
Quipt Home Medical (TSXV:QIPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Quipt Home Medical (TSXV:QIPT)
Historical Stock Chart
From Apr 2023 to Apr 2024